Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Not the traditional targeted MAB therapy which targets a specific antigen such as CD20 but targeted to the EGFR/HER2 exon 20 insertion mutation (in pozi's case). Next generation TKIs, in general, exhibit toxicity such as diarrhea which I suspect is a result of the irreversible bond to the mutation as opposed to 1st gen TKIs which bond reversibly to say, EGFR, which results in less toxicity. Why are CAR-Ts so toxic (but effective in blood cancers)? is because it targets an antigen in B cells which are prevalent throughout the body hence more toxicity. Anyhows, just some musings of no particular importance.